ライフサイエンスコーパス: nasal polyp

1 in patients with chronic rhinosinusitis with nasal polyps.

2 jects and patients with CRS with and without nasal polyps.

3 respiratory mucosal leucocytes isolated from nasal polyps.

4 in ALI cultures from patients with CRS with nasal polyps.

5 uropean Position Paper on Rhinosinusitis and Nasal Polyps.

6 l subjects and CRS patients with and without nasal polyps.

7 epithelium, a pattern also observed in human nasal polyps.

8 the chronic inflammatory response within the nasal polyps.

9 reported based on the presence or absence of nasal polyps.

10 ntagonist may be considered in patients with nasal polyps.

11 rosis, CRS without nasal polyps, or CRS with nasal polyps.

12 9 was reported in patients with recalcitrant nasal polyps.

13 ssue remodeling and pathogenesis of CRS with nasal polyps.

14 or trait, such as the presence or absence of nasal polyps.

15 adenoidal hypertrophy, septal deviation and nasal polyps.

16 chic disorders (2.87, 0.89-9.30-borderline), nasal polyps (1.86, 0.88-3.89-borderline), partial/poor

17 gnificant risk factor for the development of nasal polyps after LTx (hazards ratio, 7.2; 95% confiden

18 barrier was found in patients with CRS with nasal polyps along with a decreased expression of TJ pro

19 biopsy specimens from patients with CRS with nasal polyps along with an irregular, patchy, and decrea

20 Nasal polyps and asthma might represent a therapeutic ch

21 iseases, such as chronic rhinosinusitis with nasal polyps and asthma, show increased nasal Staphyloco

22 rgic disorders, including atopic dermatitis, nasal polyps and asthma, which are characterized by tiss

23 ould be a treatment option for patients with nasal polyps and asthma.

24 Among patients with nasal polyps and chronic rhinosinusitis, the prevalence

25 dy of allergic and nonallergic patients with nasal polyps and comorbid asthma (n = 24) was conducted.

26 ical efficacy of omalizumab in patients with nasal polyps and comorbid asthma.

27 with later-onset, mostly severe asthma with nasal polyps and eosinophilia characterized cluster 5.

28 iratory tract using in situ hybridization on nasal polyps and reverse transcriptase PCR of pharyngeal

29 OSM levels in lysates of nasal polyps and uncinate tissue positively correlated w

30 evere airway hyperresponsiveness, more often nasal polyps, and higher levels of blood neutrophils as

31 patients with chronic rhinosinusitis without nasal polyps, and patients with chronic sinusitis with n

32 Charts with search terms for asthma, nasal polyps, and record of respiratory (cohort A) or un

33 ided into 2 major subgroups based on whether nasal polyps are present or absent.

34 have been long recognized, with and without nasal polyps, are each now known to be heterogeneous, ba

35 Using organ-cultured nasal polyps as a surrogate tissue for human bronchial m

36 ession of the alarmin-like cytokine IL-33 in nasal polyps, as compared with polyps from aspirin-toler

37 Covalent dimer LTC(4)S was observed in nasal polyp biopsies, indicating that dimerization and i

38 nic hyperplastic eosinophilic sinusitis with nasal polyps, blood eosinophilia, and increased concentr

39 red with mometasone alone reduced endoscopic nasal polyp burden after 16 weeks.

40 pithelial cells and cells derived from human nasal polyps, but these reagents did not affect CaMK II-

41 ction of IL-10, but not IL-5 or IFN-gamma by nasal polyp cell suspensions.

42 en-specific IL-5 and IFN-gamma production by nasal polyp cells.

43 -phosphodiesterase inhibitors in transformed nasal polyp (CF-T43) cells homozygous for the deltaF508

44 e for SAgs in respiratory disorders, such as nasal polyps, chronic obstructive pulmonary disease, chr

45 sinus epithelial tissue of CRS patients with nasal polyps compared with healthy subjects (P = 0.01).

46 and protein levels were highly increased in nasal polyps compared with those seen in control uncinat

47 onditions for chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with na

48 Chronic rhinosinusitis (CRS) without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP)

49 patients with chronic rhinosinusitis without nasal polyps (CRSsNP) in comparison with normal subjects

50 (CRS) with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP), allergic rhinitis (AR) and contro

51 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal

52 RS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP), or with allergic rhinitis (AR), a

53 f CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP).

54 nd those with chronic rhinosinusitis without nasal polyps (CRSsNP; P < .01).

55 ence of FLCs in CRS patients with or without nasal polyps (CRSw/sNP) was investigated and the effect

56 of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and those with chronic rhinosinusi

57 in 5 years after a new diagnosis of CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP).

58 ) without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP) are associated with Th1 and Th2 cy

59 of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) are resistant to oral corticostero

60 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory conditio

61 Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with T(H)2-dominant

62 Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with TH2-dominant in

63 Although chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) is characterized by T(H)2 inflamma

64 Although chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by Th2 inflammati

65 -L1 and PD-L2 in chronic rhinosinusitis with nasal polyps (CRSwNP) is poorly studied.

66 nonasal biopsies from patients with CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsN

67 ients with chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP),

68 ILC2s were significantly enriched in nasal polyps (CRSwNP) patients.

69 yps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP) using real-world clinical practice

70 polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respirato

71 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

72 ps, and patients with chronic sinusitis with nasal polyps (CRSwNP).

73 sion in sinus tissues from CRS patients with nasal polyps demonstrated a potential role for IL-32 in

74 Primary cultures of nasal polyp epithelia from CF patients (delta F508 homoz

75 he European guidelines on rhinosinusitis and nasal polyps (EPOS 2012), CT is used as the main imaging

76 immunopathogenesis of subjects with CRS and nasal polyps experiencing exacerbation.

77 Mast cells sorted from nasal polyps expressed PGD2 synthase (hematopoietic PGD2

78 leaved active form of TSLP were increased in nasal polyps from patients with AERD relative to those i

79 s of control subjects (NM-C, n = 8) and from nasal polyps from patients with aspirin-exacerbated resp

80 Nasal polyps from subjects with AERD contained many extr

81 Primary cells isolated from CF nasal polyps gave similar results.

82 a severe form of chronic rhinosinusitis with nasal polyps in which nearly all patients express anti-S

83 Chronic rhinosinusitis with nasal polyps is associated with local immunoglobulin hyp

84 Chronic rhinosinusitis with nasal polyps is characterized by TH2-biased eosinophilic

85 terotoxin (superantigen)-specific IgE in the nasal polyp mucosa.

86 Edema represents a key feature of nasal polyp (NP) disease.

87 ucin 4 (MUC4)-tethered mucin is expressed in nasal polyp (NP) epithelial cells and upregulated under

88 subjects (P=0.06), and epithelial cells from nasal polyp (NP) tissue (P < 0.05).

89 ects (n = 12), subjects with CRS but without nasal polyps (NP) (CRSsNP, n = 12) and with CRS with NP

90 Chronic rhinosinusitis with nasal polyps (NP) and allergic rhinitis (AR) is characte

91 were purified with protein A/G columns from nasal polyps (NP), matching patient serum, and control s

92 inflammation in nasal epithelial cells from nasal polyps (NP).

93 ma proteins is a prominent characteristic of nasal polyps (NP).

94 Nasal polyps (NPs) are characterized by intense edema or

95 the PLUNC family were profoundly reduced in nasal polyps (NPs) compared to uncinate tissue from cont

96 Nasal polyps (NPs) from patients with CRS had increased

97 Tryptase mRNA was significantly increased in nasal polyps (NPs) from patients with CRSwNP (P< .001) c

98 LP) is known to be elevated and truncated in nasal polyps (NPs) of patients with chronic rhinosinusit

99 LP) is known to be elevated and truncated in nasal polyps (NPs) of patients with chronic rhinosinusit

100 t oncostatin M (OSM) levels are increased in nasal polyps (NPs) of patients with chronic rhinosinusit

101 ncreased TSLP mRNA levels have been found in nasal polyps (NPs), expression of TSLP protein and its f

102 r, the presence of DCs in CRS, especially in nasal polyps (NPs), has not been extensively studied.

103 A subset of CRS patients develop nasal polyps (NPs), which are characterized by type 2 in

104 rast to chronic rhinosinusitis (CRS) without nasal polyps (NPs).

105 isolate single SAE-specific B cells from the nasal polyps of 3 patients with aspirin-exacerbated resp

106 Adult patients with nasal polyps often have comorbid asthma, adding to the s

107 groups based on underlying disease (asthma, nasal polyps or chronic rhinosinusitis, or both), as wel

108 n patients with cystic fibrosis, CRS without nasal polyps, or CRS with nasal polyps.

109 The current serum-free nasal polyp organ culture model allows physiologically a

110 ptoms compared with placebo in patients with nasal polyps (P < .01).

111 was measured in serum and nasal secretion of nasal polyp patients treated with methylprednisolone, do

112 30% of B cells, plasma cells, and T cells in nasal polyps re-express both RAG1 and RAG2, required for

113 e dose of aspirin desensitization to prevent nasal polyp recurrence on the one hand and to minimize a

114 ose of 100 mg daily has a positive impact on nasal polyp relapse and seems to be a safe and suitable

115 After 36 months, nasal polyp relapse was less frequent (P = 0.0785) and t

116 Change in endoscopic nasal polyp score (range, 0-8; higher scores indicate wo

117 based on a composite end point of endoscopic nasal polyp score and nasal polyposis severity visual an

118 The least squares (LS) mean change in nasal polyp score was -0.3 (95% CI, -1.0 to 0.4) with pl

119 sal polyposis severity VAS score, endoscopic nasal polyp score, all individual VAS symptom scores, an

120 sal polyposis severity VAS score, endoscopic nasal polyp score, improvement in individual VAS symptom

121 Nasal polyp specimens from patients with AERD and chroni

122 been described in patients with recalcitrant nasal polyps, suggesting a link to persistent infection.

123 Nineteen patients had nasal polyps that were resistant to oral corticosteroids

124 essing TH2 effector cells were identified in nasal polyp tissue but not the healthy nasal mucosa or p

125 Nasal polyp tissue was harvested from 24 patients sensit

126 The expression of FLCs in nasal polyp tissue was investigated using immunohistoche

127 alveolar lavage fluid, lung tissue, or human nasal polyp tissue were analyzed by means of Western blo

128 onfirmed the increased FLC concentrations in nasal polyp tissue.

129 ithelial cells from control nasal tissue and nasal polyp tissue.

130 ting eosinophils exhibited EETs in patients' nasal polyp tissues.

131 human bronchial epithelial cells (NHBEs) and nasal polyp tissues.

132 Whole nasal polyp TSLP mRNA expression correlated strongly wit

133 to severe bronchial hyperresponsiveness and nasal polyps were independent predictors of asthma persi

134 hospholipase A2, and LT enzymes in NHBEs and nasal polyps were refractory to corticosteroids.

135 Immunohistochemistry on human nasal polyp with antieotaxin mAbs showed that certain le

136 trated clinical efficacy in the treatment of nasal polyps with comorbid asthma, supporting the import